Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 5
Submit an article Journal homepage
1,521
Views
31
CrossRef citations to date
0
Altmetric
Author's View

CD73-adenosine reduces immune responses and survival in ovarian cancer patients

Pierre-Olivier GaudreauCentre de Recherche du Centre Hospitalier de l'Université de Montréal et Institut du Cancer de Montréal, Québec, Canada;Faculté de Pharmacie, Université de Montréal, Québec, Canada
,
Bertrand AllardCentre de Recherche du Centre Hospitalier de l'Université de Montréal et Institut du Cancer de Montréal, Québec, Canada;Faculté de Pharmacie, Université de Montréal, Québec, Canada
,
Martin TurcotteCentre de Recherche du Centre Hospitalier de l'Université de Montréal et Institut du Cancer de Montréal, Québec, Canada;Faculté de Pharmacie, Université de Montréal, Québec, Canada
&
John StaggCentre de Recherche du Centre Hospitalier de l'Université de Montréal et Institut du Cancer de Montréal, Québec, Canada;Faculté de Pharmacie, Université de Montréal, Québec, CanadaCorrespondence[email protected]
Article: e1127496 | Received 23 Nov 2015, Accepted 27 Nov 2015, Published online: 31 May 2016

References

  • Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS ONE 2009; 4:e6412; PMID:19641607; http://dx.doi.org/10.1371/journal.pone.0006412
  • Allard B, Turcotte M, Stagg J. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Expert Opin. Ther. Targets 2014; 18:863-81; PMID:24798880; http://dx.doi.org/10.1517/14728222.2014.915315
  • Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol. Med. 2013; 19:355-67; PMID:23601906; http://dx.doi.org/10.1016/j.molmed.2013.03.005
  • Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. 2010; 107:1547-52; PMID:20080644; http://dx.doi.org/10.1073/pnas.0908801107
  • Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010; 70:2245-55; PMID:20179192; http://dx.doi.org/10.1158/0008-5472.CAN-09-3109
  • Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MWL, Darcy PK, Smyth MJ. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011; 71:2892-900; PMID:21292811; http://dx.doi.org/10.1158/0008-5472.CAN-10-4246
  • Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res. 2013; 19:5626-35; PMID:23983257; http://dx.doi.org/10.1158/1078-0432.CCR-13-0545
  • Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol. Res. 2015; 3:506-17; PMID:25672397; http://dx.doi.org/10.1158/2326-6066.CIR-14-0211
  • Mittal D, Young A, Stannard K, Yong M, Teng MWL, Allard B, Stagg J, Smyth MJ. Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 2014; 74:3652-8; PMID:24986517; http://dx.doi.org/10.1158/0008-5472.CAN-14-0957
  • Turcotte M, Spring K, Pommey S, Chouinard G, Cousineau I, George J, Chen GM, Gendoo DMA, Haibe-Kains B, Karn T et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 2015; 75:4494-503; PMID:26363007; http://dx.doi.org/10.1158/0008-5472.CAN-14-3569

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.